4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ProQR Therapeutics N.V. (PRQR) operates in the Biotechnology industry and is headquartered in Leiden, Netherlands with about 186 employees. Its market capitalization is roughly $243 million. In the fiscal year ended 2025-12-31, PRQR reported $16M in revenue and ($42M) in net income.
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Interactive charts & full statements → Open the PRQR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $16M | $19M | $6M | $4M | — |
| Operating Income (EBIT) | ($43M) | ($30M) | ($35M) | ($65M) | — |
| Net Income | ($42M) | ($28M) | ($28M) | ($64M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $2M | $5M | $3M | $4M | $4M | — |
| Operating Income (EBIT) | ($14M) | ($9M) | ($11M) | ($12M) | ($11M) | — |
| Net Income | ($13M) | ($9M) | ($11M) | ($12M) | ($10M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $113M | $168M | $138M | $171M | — |
| Total Liabilities | $63M | $79M | $96M | $105M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRQR viewer.
About TickerBase · Data methodology & sources